References
[1]. “World Health Organization., “Cancer,” World Health Organization, 3 February 2022, <https://www.who.int/news-room/fact-sheets/detail/cancer> (20 May 2023).
[2]. Zhao, T., Ren, H., Jia, L., Chen, J., Xin, W., et al., “Inhibition of HIF-1 alpha by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma,” Oncotarget 6(4), 2250–2262 (2015).
[3]. Muz, B., de la Puente, P., Azab, F. and Azab, A. K., “The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy,” Hypoxia (Auckl) 3, 83–92 (2015).
[4]. Lee, K. and Kim, H. M., “A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor,” Arch. Pharm. Res. 34(10), 1583–1585 (2011).
[5]. Luo, F., Lu, F.-T., Cao, J.-X., Ma, W.-J., Xia, Z.-F., et al, “HIF-1 alpha inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer,” Cancer Lett. 531, 39–56 (2022).
[6]. Zhu, Y., Zang, Y., Zhao, F., Li, Z., Zhang, J., et al., “Inhibition of HIF-1α by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo,” Am J Cancer Res 7(5), 1198–1212 (2017).
[7]. Jacoby, J. J., Erez, B., Korshunova, M. V., Williams, R. R., Furutani, K., et al, “Treatment with HIF-1 alpha Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice,” J. Thorac. Oncol. 5(7), 940–949 (2010).
[8]. Schwartz, D. L., Powis, G., Thitai-Kumar, A., He, Y., Bankson, J., et al., “The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects,” Molecular cancer therapeutics 8(4), 947–958 (2009).
[9]. Palayoor, S. T., Mitchell, J. B., Cerna, D., DeGraff, W., John-Aryankalayil, M., et al., “PX-478, an inhibitor of hypoxia-inducible factor-1α, enhances radiosensitivity of prostate carcinoma cells,” International Journal of Cancer 123(10), 2430–2437 (2008).
[10]. Schwartz, D. L., Bankson, J. A., Lemos, R., Jr., Lai, S. Y., Thittai, A. K., et al., “Radiosensitization and Stromal Imaging Response Correlates for the HIF-1 Inhibitor PX-478 Given with or without Chemotherapy in Pancreatic Cancer,” Molecular Cancer Therapeutics 9(7), 2057–2067 (2010).
[11]. Lang, M., Wang, X., Wang, H., Dong, J., Lan, C., et al., “Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma,” Cancer Letters 378(2), 87–96 (2016).
[12]. Parczyk, J., Ruhnau, J., Pelz, C., Schilling, M., Wu, H., et al., “Dichloroacetate and PX-478 exhibit strong synergistic effects in a various number of cancer cell lines,” BMC Cancer 21(1), 481 (2021).
[13]. Li, H., Sun, X., Li, J., Liu, W., Pan, G., et al., “Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1α/miR-494/Survivin signaling pathway,” Neoplasia 32, 100821 (2022).
[14]. Goodla, L. and Xue, X., “The Role of Inflammatory Mediators in Colorectal Cancer Hepatic Metastasis,” Cells 11(15), 2313 (2022).
[15]. Sun, S., Guo, C., Gao, T., Ma, D., Su, X., et al., “Hypoxia Enhances Glioma Resistance to Sulfasalazine-Induced Ferroptosis by Upregulating SLC7A11 via PI3K/AKT/HIF-1 alpha Axis,” Oxidative Med. Cell. Longev. 2022, 7862430 (2022).
[16]. Ryu, J.-S., Sim, S. H., Park, I. H., Lee, E. G., Lee, E. S., et al., “Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer,” Cancers 11(4), 574 (2019).
[17]. Sun, K., Halberg, N., Khan, M., Magalang, U. J. and Scherer, P. E., “Selective Inhibition of Hypoxia-Inducible Factor 1α Ameliorates Adipose Tissue Dysfunction,” Molecular and Cellular Biology 33(5), 904–917 (2013).
[18]. Villa-Roel, N., Ryu, K., Gu, L., Fernandez Esmerats, J., Kang, D.-W., et al, “Hypoxia inducible factor 1α inhibitor PX-478 reduces atherosclerosis in mice,” Atherosclerosis 344, 20–30 (2022).
[19]. Ilegems, E., Bryzgalova, G., Correia, J., Yesildag, B., Berra, E., Ruas, et al, “HIF-1α inhibitor PX-478 preserves pancreatic β cell function in diabetes,” Science Translational Medicine (2022).
Cite this article
Zhang,L. (2023). HIF-1α inhibitor PX-478 for cancer therapy and other fields. Theoretical and Natural Science,21,258-263.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).
References
[1]. “World Health Organization., “Cancer,” World Health Organization, 3 February 2022, <https://www.who.int/news-room/fact-sheets/detail/cancer> (20 May 2023).
[2]. Zhao, T., Ren, H., Jia, L., Chen, J., Xin, W., et al., “Inhibition of HIF-1 alpha by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma,” Oncotarget 6(4), 2250–2262 (2015).
[3]. Muz, B., de la Puente, P., Azab, F. and Azab, A. K., “The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy,” Hypoxia (Auckl) 3, 83–92 (2015).
[4]. Lee, K. and Kim, H. M., “A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor,” Arch. Pharm. Res. 34(10), 1583–1585 (2011).
[5]. Luo, F., Lu, F.-T., Cao, J.-X., Ma, W.-J., Xia, Z.-F., et al, “HIF-1 alpha inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer,” Cancer Lett. 531, 39–56 (2022).
[6]. Zhu, Y., Zang, Y., Zhao, F., Li, Z., Zhang, J., et al., “Inhibition of HIF-1α by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo,” Am J Cancer Res 7(5), 1198–1212 (2017).
[7]. Jacoby, J. J., Erez, B., Korshunova, M. V., Williams, R. R., Furutani, K., et al, “Treatment with HIF-1 alpha Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice,” J. Thorac. Oncol. 5(7), 940–949 (2010).
[8]. Schwartz, D. L., Powis, G., Thitai-Kumar, A., He, Y., Bankson, J., et al., “The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects,” Molecular cancer therapeutics 8(4), 947–958 (2009).
[9]. Palayoor, S. T., Mitchell, J. B., Cerna, D., DeGraff, W., John-Aryankalayil, M., et al., “PX-478, an inhibitor of hypoxia-inducible factor-1α, enhances radiosensitivity of prostate carcinoma cells,” International Journal of Cancer 123(10), 2430–2437 (2008).
[10]. Schwartz, D. L., Bankson, J. A., Lemos, R., Jr., Lai, S. Y., Thittai, A. K., et al., “Radiosensitization and Stromal Imaging Response Correlates for the HIF-1 Inhibitor PX-478 Given with or without Chemotherapy in Pancreatic Cancer,” Molecular Cancer Therapeutics 9(7), 2057–2067 (2010).
[11]. Lang, M., Wang, X., Wang, H., Dong, J., Lan, C., et al., “Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma,” Cancer Letters 378(2), 87–96 (2016).
[12]. Parczyk, J., Ruhnau, J., Pelz, C., Schilling, M., Wu, H., et al., “Dichloroacetate and PX-478 exhibit strong synergistic effects in a various number of cancer cell lines,” BMC Cancer 21(1), 481 (2021).
[13]. Li, H., Sun, X., Li, J., Liu, W., Pan, G., et al., “Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1α/miR-494/Survivin signaling pathway,” Neoplasia 32, 100821 (2022).
[14]. Goodla, L. and Xue, X., “The Role of Inflammatory Mediators in Colorectal Cancer Hepatic Metastasis,” Cells 11(15), 2313 (2022).
[15]. Sun, S., Guo, C., Gao, T., Ma, D., Su, X., et al., “Hypoxia Enhances Glioma Resistance to Sulfasalazine-Induced Ferroptosis by Upregulating SLC7A11 via PI3K/AKT/HIF-1 alpha Axis,” Oxidative Med. Cell. Longev. 2022, 7862430 (2022).
[16]. Ryu, J.-S., Sim, S. H., Park, I. H., Lee, E. G., Lee, E. S., et al., “Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer,” Cancers 11(4), 574 (2019).
[17]. Sun, K., Halberg, N., Khan, M., Magalang, U. J. and Scherer, P. E., “Selective Inhibition of Hypoxia-Inducible Factor 1α Ameliorates Adipose Tissue Dysfunction,” Molecular and Cellular Biology 33(5), 904–917 (2013).
[18]. Villa-Roel, N., Ryu, K., Gu, L., Fernandez Esmerats, J., Kang, D.-W., et al, “Hypoxia inducible factor 1α inhibitor PX-478 reduces atherosclerosis in mice,” Atherosclerosis 344, 20–30 (2022).
[19]. Ilegems, E., Bryzgalova, G., Correia, J., Yesildag, B., Berra, E., Ruas, et al, “HIF-1α inhibitor PX-478 preserves pancreatic β cell function in diabetes,” Science Translational Medicine (2022).